| 1.85 -0.02 (-1.07%) | 09-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.76  |
1-year : | 3.16 |
| Resists | First : | 2.36 |
Second : | 2.71 |
| Pivot price | 2.08 |
|||
| Supports | First : | 1.81 |
Second : | 1.5 |
| MAs | MA(5) : | 1.91 |
MA(20) : | 2.1 |
| MA(100) : | 1.83 |
MA(250) : | 1.79 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 4.8 |
D(3) : | 4.7 |
| RSI | RSI(14): 39.4 |
|||
| 52-week | High : | 2.71 | Low : | 1.16 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IPHA ] has closed above bottom band by 5.7%. Bollinger Bands are 10.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.91 - 1.93 | 1.93 - 1.94 |
| Low: | 1.77 - 1.8 | 1.8 - 1.81 |
| Close: | 1.82 - 1.86 | 1.86 - 1.88 |
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory conditions. IPH5201: A blocking antibody in Phase I trials, focused on the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody developed to enhance anti-tumor immunity by targeting the immunosuppressive adenosine pathway. IPH6101: An NKp46-based NK cell engager being evaluated for the generation of up to two bispecific NK cell engagers. Innate Pharma also maintains an active preclinical pipeline, including IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. The company has established strategic licensing and collaboration agreements with major industry players such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, alongside a co-development and license agreement with MedImmune Limited.
Thu, 10 Sep 2026
Cancer immunotherapy firm Innate Pharma (IPHA) plans Sept. 17 business update call - Stock Titan
Thu, 10 Sep 2026
Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update - Yahoo Finance
Wed, 02 Sep 2026
Innate Pharma (Nasdaq: IPHA) plans fireside chat at H.C. Wainwright investor conference - Stock Titan
Tue, 01 Sep 2026
Innate Pharma to Participate in H.C. Wainwright Conference - Intellectia AI
Fri, 14 Aug 2026
Innate Pharma Secures €30M, Extends Cash Runway Into 2028 - TradingView
Fri, 14 Aug 2026
Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares - businesswire.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 112 (M) |
| Shares Float | 71 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 0.3 (%) |
| Shares Short | 227 (K) |
| Shares Short P.Month | 164 (K) |
| EPS | -0.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.28 |
| Profit Margin | 0 % |
| Operating Margin | -689.6 % |
| Return on Assets (ttm) | -38.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -46.8 % |
| Gross Profit (p.s.) | -0.31 |
| Sales Per Share | 0.08 |
| EBITDA (p.s.) | -0.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -2.9 |
| PEG Ratio | 0 |
| Price to Book value | -6.86 |
| Price to Sales | 22.93 |
| Price to Cash Flow | -3.92 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|